Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 281.02M -33.9% |
| Revenue (ttm) | n/a |
| Net Income | -17.25M |
| EPS | -0.15 |
| Shares Out | 109.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,281,593 |
| Open | 2.580 |
| Previous Close | 2.580 |
| Day's Range | 2.500 - 2.670 |
| 52-Week Range | 2.165 - 5.450 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 8.58 (+235.12%) |
| Est. Earnings | Nov 9, 2026 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardia... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $8.58, which is an increase of 235.12% from the latest price.
News
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseas...
Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral from Sell with a price target of $4, up from $3 after the company provided a comprehensive update on RP-A501 in Danon…
Rocket Pharmaceuticals highlights FDA-aligned Phase 2 trial of RP-A501
Rocket Pharmaceuticals (RCKT) highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FD...
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseas...
Rocket Pharmaceuticals Transcript: Status update
Phase I data showed sustained LAMP2 expression and cardiac improvements, while 3 patients on the revised phase II regimen completed initial monitoring without severe complement-mediated toxicity. The pivotal study targets 7 responders among 12 by 12 months, with dosing expected to finish by mid-2027.
Rocket Pharmaceuticals Slides: Status update
Rocket Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 6, 2026.
Rocket Pharmaceuticals secures $150M credit facility from Hercules Capital
Rocket Pharmaceuticals (RCKT) “announced that it has entered into a credit facility agreement with Hercules Capital (HTGC) for up to $150 million. The facility strengthens Rocket’s financial position ...
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening disea...
Needham upgrades Rocket Pharmaceuticals after FDA reaffirms Danon study design
As previously reported, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy from Hold with a $9 price target after the FDA reaffirmed the pivotal study design for RP-A501 in Danon Disease,…
Rocket Pharmaceuticals upgraded to Buy from Hold at Needham
Needham analyst Gil Blum upgraded Rocket Pharmaceuticals (RCKT) to Buy from Hold with a $9 price target
Rocket Pharmaceuticals Transcript: Study update
Three cardiovascular gene therapy programs are advancing, with the Danon pivotal trial cleared to resume dosing after safety modifications and robust patient identification. Durable efficacy is seen in long-term follow-up, and regulatory interactions remain positive. Cash runway extends into 2028.
Rocket Pharmaceuticals Press release: Study update
Rocket Pharmaceuticals issued a press release on September 15, 2026, disclosing material business information to investors.
Rocket Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing three cardiovascular gene therapy programs, with the Danon disease trial cleared by the FDA to proceed at a recalibrated dose and revised safety regimen. Strong cash reserves support ongoing trials, and a comprehensive update is planned for October 6th. Early data in PKP2 and BAG3 show promising efficacy and safety.
Rocket announces FDA alignment on path to complete Phase 2 trial of RP-A501
Rocket Pharmaceuticals (RCKT) announced alignment with the U.S. Food and Drug Administration, FDA, on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501…
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening disea...
Rocket Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing gene therapies for rare cardiomyopathies, with a pivotal Danon trial underway and a Q4 launch for KRESLADI. Patient identification is improving through genetic testing initiatives and community outreach, while safety and efficacy are being optimized via dose adjustments and robust trial design.
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, ...
Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush
Wedbush lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $16 after model adjustments, while keeping an Outperform rating on the shares. The firm says the Q2…
Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c
As of June 30, 2026, Rocket had cash, cash equivalents and investments of $283.7 million. Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as…
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, ...
Rocket Pharmaceuticals Quarterly report: Q2 2026
Rocket Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 10, 2026.
Rocket Pharmaceuticals Earnings release: Q2 2026
Rocket Pharmaceuticals released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Rocket announces safety update from three patients treated with RP-A501
Rocket Pharmaceuticals (RCKT) announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global Phase 2 trial of RP-A501 in Danon dise...
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare an...
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
Rocket Pharmaceuticals (RCKT) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher, PRV, for gross proceeds of $180M. The Rare Pediatric Disease Priority Review Vouc...